These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

696 related articles for article (PubMed ID: 23704171)

  • 1. Risk of incident diabetes among patients treated with statins: population based study.
    Carter AA; Gomes T; Camacho X; Juurlink DN; Shah BR; Mamdani MM
    BMJ; 2013 May; 346():f2610. PubMed ID: 23704171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
    Ramachandran S; Saraf S; Shetty C; Capps N; Bailey C
    Ann Clin Biochem; 2011 Jan; 48(Pt 1):75-8. PubMed ID: 21115572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
    Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
    Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
    Hoffman KB; Kraus C; Dimbil M; Golomb BA
    PLoS One; 2012; 7(8):e42866. PubMed ID: 22936996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
    Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
    Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.
    Dormuth CR; Hemmelgarn BR; Paterson JM; James MT; Teare GF; Raymond CB; Lafrance JP; Levy A; Garg AX; Ernst P;
    BMJ; 2013 Mar; 346():f880. PubMed ID: 23511950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients.
    Singh S; Willig JH; Mugavero MJ; Crane PK; Harrington RD; Knopp RH; Kosel BW; Saag MS; Kitahata MM; Crane HM
    Clin Infect Dis; 2011 Feb; 52(3):387-95. PubMed ID: 21189273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
    Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
    Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
    Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S
    Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
    McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
    Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
    Strutt K; Caplan R; Hutchison H; Dane A; Blasetto J
    Circ J; 2004 Feb; 68(2):107-13. PubMed ID: 14745143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
    Karie S; Launay-Vacher V; Deray G; Isnard-Bagnis C
    Presse Med; 2006 Feb; 35(2 Pt 1):219-29. PubMed ID: 16493350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes.
    Mori Y; Kuriyama G; Tanaka T; Tajima N
    Endocrine; 2009 Dec; 36(3):412-8. PubMed ID: 19834827
    [No Abstract]   [Full Text] [Related]  

  • 16. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
    Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
    Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors.
    Calza L; Manfredi R; Colangeli V; Pocaterra D; Pavoni M; Chiodo F
    Curr HIV Res; 2008 Nov; 6(6):572-8. PubMed ID: 18991624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial.
    Insull W; Ghali JK; Hassman DR; Y As JW; Gandhi SK; Miller E;
    Mayo Clin Proc; 2007 May; 82(5):543-50. PubMed ID: 17493418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of statin therapy due to muscular side effects: a survey in real life.
    Rosenbaum D; Dallongeville J; Sabouret P; Bruckert E
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):871-5. PubMed ID: 22748604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database.
    Palmer MK; Nicholls SJ; Lundman P; Barter PJ; Karlson BW
    Eur J Prev Cardiol; 2013 Dec; 20(6):1080-7. PubMed ID: 23644489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.